Newsroom

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

1 min read

Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals

Apr 30, 2013 2:30:45 PM

Funding to Expand the SUREtechnology Platform™

Geneva, Switzerland (PRNEWSWIRE) April 30, 2013 – Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that it has closed an agreement with Ligand Pharmaceuticals Incorporated to sell potential milestone and royalty payments for more than 15 biologic development programs from Selexis.

The acquired programs are in various preclinical and clinical stages. Funds from the Ligand deal will be used for R&D to further develop the next generation of SUREtechnology Platform™ products. Torreya Partners acted as financial advisor to Selexis. Selexis currently holds milestone and potential royalty interest payment rights to an additional 14 biologic development programs not included in the Ligand deal.

“With this truly innovative financing solution, Selexis was able to leverage a percentage of potential future revenues to fund, reinforce and expand our SUREtechnology Platform,” said Dr. Igor Fisch, CEO, Selexis SA. “The non-diluting funds will support the growth of our products and technologies faster. The Company’s SUREtechnology Platform is a powerful engine that continues to fuel royalty opportunities for Selexis.”

Featured